Verici Dx announced an exciting collaboration with The Westmead Institute for Medical Research based in Sydney, Australia, on a newly awarded, 4-year federal research grant. This forms part of the Australian Government's Medical Research Future Fund (MRFF) "Genomics Health Futures Mission". Through the Genomics Health Futures Mission, the Australian Government is investing AUD 500 million in genomic medicine research with the objective to save or transform the lives of more than 200,000 Australians through genomic research to deliver better testing, diagnosis, and treatment, including in the field of organ transplants.

The collaboration between Verici Dx and The Westmead Institute for Medical Research aims to improve the understanding of factors contributing to graft loss in organ transplants, focusing on genetic differences between donor and recipient beyond the well-known HLA1 mismatches. By incorporating a broader range of genetic data through multiple cohorts with varying ethnic backgrounds, the goal is to enhance the prediction and management of risks associated with organ transplants, ultimately leading to better outcomes for patients. Verici Dx will use its CAP/CLIA-certified laboratory to perform sequencing from blood samples across 3 sites, as well as apply its existing biomarker tests to the samples to assess their use in this diverse population.

In addition to the research, the programme also involves a health economics analysis, an important step for new assays (tests) to be officially recognised and approved for use in Australia.